How long does 25C-NBOMe last?

The total duration of 25C-NBOMe via sublingual is 8 hours to 10 hours. Onset typically occurs within 15 minutes. Peak effects last 4 hours to 6 hours.

25C-NBOMe — SubstanceWiki

25C-NBOMe (2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine, also known as NBOMe-2C-C) is a synthetic psychedelic phenethylamine and close structural analog of 2C-C, belonging to the NBOMe series. It is one of the three most common NBOMe compounds encountered in forensic drug checking (alongside 25I-NBOMe and 25B-NBOMe) and is directly associated with multiple confirmed human fatalities.

Like all NBOMe compounds, 25C-NBOMe is active at microgram doses (as low as 200–400 μg produces noticeable effects; 600–1,200 μg is the range at which most recreational experiences occur) and is only effective via sublingual or buccal administration. The compound has been widely distributed on blotter paper, frequently sold as LSD, and its dangerous overlap in appearance with LSD blotters has been a central driver of NBOMe-related harm.

The 4-chloro substitution gives 25C-NBOMe a slightly milder and shorter-acting profile compared to 25I-NBOMe (the most dangerous of the major NBOMe compounds), but it remains a potently toxic substance with confirmed fatalities. Cardiovascular effects, vasoconstriction, hyperthermia, and seizures represent the primary mechanisms of acute toxicity. Any blotter sold as or suspected to be an NBOMe compound must be approached with extreme caution, and the same harm reduction framework applicable to 25I-NBOMe applies in full.

How It Feels

Within fifteen minutes of holding the blotter against the gum, the bitter chemical taste has permeated the mouth and a sharp, buzzing energy starts to climb the spine. The onset is faster and more assertive than 25C-NBOH. Heart rate picks up noticeably, and there is an immediate tightening in the peripheral blood vessels -- fingers cool, toes tingle, and the jaw begins to clench. Colors in the visual field start to bleed and intensify, as though the contrast on a screen has been cranked upward while the hue slider shifts freely.

By forty-five minutes, the world has been transformed into a vivid, saturated lightshow. Colors are extraordinarily bright and seem to pulse with their own internal rhythm. Visual geometry appears as flowing, colorful patterns that overlay surfaces with moderate density -- less aggressively mathematical than 25I-NBOMe but more intense than the gentler 2C compounds. Walls breathe, textures ripple, and objects acquire shimmering auras of complementary color. There is a pronounced color-shifting effect where surfaces cycle through hues in slow, mesmerizing waves. The stimulant component is significant but manageable -- a persistent buzzing energy that drives a desire to move, explore, and engage with the environment.

The peak plateau lasts roughly two to three hours and is characterized by strong visual activity paired with a relatively clear headspace. Thoughts move quickly but remain coherent. There is an emotional brightness and a tendency toward laughter and playfulness. Music is dramatically enhanced, with bass frequencies seeming to physically vibrate through the body and melodies acquiring vivid synesthetic color associations. The body load is present but less punishing than 25B-NBOMe or 25I-NBOMe -- vasoconstriction and jaw tension are noticeable without being dominant. Nausea may appear in brief waves but rarely persists.

Compared to classical psychedelics, the duration is compact. Effects begin to diminish around four to five hours after onset, with the visual fireworks dimming to a pleasant shimmer. The stimulant energy gradually dissipates, replaced by a tired but not unpleasant fatigue. The total experience spans five to eight hours. The comedown can leave a feeling of being physically wrung out -- residual tension in the shoulders and jaw, mild dehydration, and occasionally a dull headache. There is often a sense of having attended a particularly vivid light show rather than having undergone a transformative inner journey.

Subjective Effects

The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.

Physical Effects

Physical(19)

Appetite suppression— A distinct decrease in hunger and desire to eat, ranging from reduced interest in food to complete d...
Body load— A diffuse, heavy physical discomfort involving tension, pressure, and malaise in the torso and limbs...
Changes in felt gravity— A distortion of one's proprioceptive sense of gravity in which the perceived direction of gravitatio...
Dehydration— A state of insufficient bodily hydration manifesting as persistent thirst, dry mouth, and physical d...
Dry mouth— A persistent, uncomfortable reduction in saliva production causing the mouth and throat to feel parc...
Frequent urination— Increased urinary frequency beyond normal patterns, caused by diuretic effects or bladder irritation...
Headache— A painful sensation of pressure, throbbing, or aching in the head that can range from a dull backgro...
Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
Increased libido— A marked enhancement of sexual desire, arousal, and sensitivity to erotic stimuli that can range fro...
Laughter fits— Spontaneous, uncontrollable, and often prolonged episodes of intense laughter that erupt without any...
Muscle tension— Persistent partial contractions or tightening of muscles that produces uncomfortable stiffness, cram...
Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
Pupil dilation— A visible enlargement of the pupil diameter (mydriasis) that can range from subtle widening to drama...
Sedation— A state of deep physical and mental calming that manifests as a progressive desire to remain still, ...
Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
Teeth grinding— An involuntary clenching and rhythmic grinding of the jaw muscles, known clinically as bruxism, that...
Vasoconstriction— A narrowing of blood vessels throughout the body that produces sensations of cold extremities, tingl...

Cognitive & Perceptual Effects

Visual(16)

After images— A visual phenomenon in which a faint, ghostly imprint of a previously viewed image persists in the v...
Colour enhancement— An intensification of the brightness, vividness, and saturation of colors in the external environmen...
Colour shifting— The visual experience of colors on objects and surfaces cycling through continuous, fluid transforma...
Diffraction— The experience of seeing rainbow-like spectrums of color and prismatic halos embedded within bright ...
Drifting— The visual experience of perceiving stationary objects, textures, and surfaces as appearing to flow,...
Environmental cubism— A visual distortion in which the environment and objects within it appear fragmented into geometric,...

Detection Methods

Urine Detection

25C-NBOMe is not targeted by standard immunoassay-based urine drug screens. However, due to its phenethylamine backbone, there is a theoretical possibility of cross-reactivity with amphetamine immunoassays, though this has not been consistently reported in clinical literature. Specialized LC-MS/MS methods developed for novel psychoactive substances can detect NBOMe compounds and their metabolites in urine for approximately 24 to 48 hours after ingestion, depending on dose and individual metabolism.

Blood and Serum Detection

Blood detection windows for 25C-NBOMe are relatively short. Peak plasma concentrations occur within 30 minutes to 2 hours depending on the route of administration (sublingual absorption is typical for NBOMe compounds). Blood concentrations fall below detectable thresholds within 6 to 16 hours for most methods. LC-MS/MS remains the only reliable analytical approach for serum detection, as the doses involved (typically hundreds of micrograms to low milligrams) produce low absolute concentrations.

Standard Drug Panel Inclusion

25C-NBOMe is NOT included on standard 5-panel, 10-panel, or 12-panel drug screens. It is not specifically targeted by any routine workplace or clinical immunoassay. While some structural similarity to amphetamines exists, cross-reactivity on amphetamine panels is inconsistent and cannot be relied upon for either detection or exclusion. Identification requires specific testing at a reference laboratory equipped for novel psychoactive substance analysis.

Confirmatory Methods

Definitive identification of 25C-NBOMe requires LC-MS/MS or high-resolution mass spectrometry (HRMS). GC-MS can also be employed but may require derivatization due to the thermal lability of NBOMe compounds. Reference standards are necessary for quantitative confirmation. Forensic and clinical toxicology laboratories that maintain novel psychoactive substance panels are the only facilities reliably capable of this analysis.

Reagent Testing (Harm Reduction)

Reagent testing is critically important for NBOMe compounds due to their significantly higher toxicity profile compared to classical psychedelics. The Ehrlich reagent shows NO reaction with 25C-NBOMe, which is the single most important distinguishing test: any substance sold as a psychedelic that fails to turn purple with Ehrlich may be an NBOMe compound rather than LSD or a tryptamine. The Marquis reagent produces variable results depending on the specific NBOMe compound, ranging from no reaction to green or brown color changes. The Mecke reagent may produce a brown or dark green reaction. For harm reduction purposes, always testing with Ehrlich first is essential. The absence of a purple Ehrlich reaction is a strong warning sign that the substance is not a lysergamide or tryptamine and may be a potentially dangerous NBOMe compound.

Interactions

Substance	Status	Note
Cocaine	Unsafe	—
3-FMA	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
4-MMC	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
8-Chlorotheophylline	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Adrafinil	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Anandamide	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
APICA	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
Atropa belladonna	Caution	Unpredictable compounding of hallucinogenic effects with anticholinergic delirium
Benzydamine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Bromantane	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Cannabidiol	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
Datura	Caution	Unpredictable compounding of hallucinogenic effects with anticholinergic delirium
Dichloropane	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Diphenhydramine	Caution	Unpredictable compounding of hallucinogenic effects with anticholinergic delirium
Ephedrine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Harmala alkaloid	Caution	MAOIs dramatically potentiate psychedelics; drastically reduce dose and exercise extreme caution
Hexedrone	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Methcathinone	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Nicotine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Oxiracetam	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Peganum harmala	Caution	MAOIs dramatically potentiate psychedelics; drastically reduce dose and exercise extreme caution
Phenylpiracetam	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Rhodiola Rosea	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Caffeine	Uncertain	—
Cannabis	Uncertain	—
MDMA	Uncertain	—
1,3-Butanediol	Low Risk & Synergy	Cross-tolerance exists; effects compound
25E-NBOH	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-T	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-T-2	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-T-21	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-T-7	Low Risk & Synergy	Cross-tolerance exists; effects compound
3-Cl-PCP	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-HO-PCE	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-HO-PCP	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-MeO-PCE	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-MeO-PCMo	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-MeO-PCP	Low Risk & Synergy	Produces unique synergistic effects; often combined
4-MeO-PCP	Low Risk & Synergy	Produces unique synergistic effects; often combined
Allylescaline	Low Risk & Synergy	Cross-tolerance exists; effects compound
Ayahuasca	Low Risk & Synergy	Cross-tolerance exists; effects compound
Deschloroketamine	Low Risk & Synergy	Produces unique synergistic effects; often combined
DET	Low Risk & Synergy	Cross-tolerance exists; effects compound
Diphenidine	Low Risk & Synergy	Produces unique synergistic effects; often combined
DiPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
DOM	Low Risk & Synergy	Cross-tolerance exists; effects compound
DPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
Efavirenz	Low Risk & Synergy	Cross-tolerance exists; effects compound
Ephenidine	Low Risk & Synergy	Produces unique synergistic effects; often combined
EPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
HXE	Low Risk & Synergy	Produces unique synergistic effects; often combined
Ibogaine	Low Risk & Synergy	Cross-tolerance exists; effects compound
Inhalants	Low Risk & Synergy	Produces unique synergistic effects; often combined
Memantine	Low Risk & Synergy	Produces unique synergistic effects; often combined
MET	Low Risk & Synergy	Cross-tolerance exists; effects compound
Methallylescaline	Low Risk & Synergy	Cross-tolerance exists; effects compound
MiPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
MPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
MXiPr	Low Risk & Synergy	Produces unique synergistic effects; often combined
O-PCE	Low Risk & Synergy	Produces unique synergistic effects; often combined
PCE	Low Risk & Synergy	Produces unique synergistic effects; often combined
Psilocybin Mushrooms	Low Risk & Synergy	Cross-tolerance exists; effects compound
Lorazepam	Low Risk & Decrease	Depressants dull psychedelic effects; benzodiazepines are commonly used as trip-killers

Showing 63 key interactions out of 84 total.

Toxicity & Safety

Confirmed Fatalities

25C-NBOMe is directly associated with confirmed human fatalities. Reports of fatal outcomes include cardiovascular collapse, seizures, hyperthermia, and multi-organ failure. The compound was identified in postmortem toxicology in multiple death cases in Europe and North America during 2012–2016.

Mechanism of Severe Toxicity

The primary mechanisms of life-threatening toxicity are:

Severe vasoconstriction — alpha-adrenergic receptor activation; can progress to vascular compromise, cardiac ischemia, and cardiovascular collapse at high doses
Hyperthermia — dangerously elevated core body temperature, particularly with physical exertion
Tonic-clonic seizures — documented in multiple cases of severe NBOMe toxicity
Rhabdomyolysis — skeletal muscle breakdown secondary to hyperthermia and seizures; leads to renal failure

Narrow Therapeutic Window

Like all NBOMe compounds, 25C-NBOMe has a narrow dose window between desired psychedelic effects and dangerous physiological toxicity. This window is compressed further by:

Batch-to-batch variation in blotter potency
Individual pharmacokinetic variation (body weight, CYP450 genotype)
Concurrent substance use (particularly stimulants)

Cardiovascular Effects

Significant tachycardia and hypertension are consistent effects. Those with pre-existing cardiovascular conditions are at dramatically elevated risk.

Drug Interactions

Stimulants — Absolutely contraindicated; synergistic vasoconstriction and cardiac risk
Lithium — Absolutely contraindicated for all psychedelics
MAOIs — Avoid; serotonin syndrome risk
Cannabis — Unpredictably amplifies intensity and psychological adverse events

Contraindications

Cardiovascular disease, hypertension, or any vascular disorder (absolute contraindication)
Personal or family history of psychotic disorders
Concurrent use of stimulants, lithium, or MAOIs

Addiction Potential

not habit-forming

Overdose Information

LD50fatal at heavy dosages.

It is advised that due to 25C-NBOMe's extreme potency it should not be insufflated (snorted) as this method of administration has been attributed to several fatal overdoses due to improper dosing.

Brazil: Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.
Canada: 25C-NBOMe would be considered Schedule III as it is a derivative of 2,5-dimethoxyphenethylamine.
China: As of October 2015 25C-NBOMe is a controlled substance in China.
Germany: 25C-NBOMe is controlled under Anlage I BtMG (Narcotics Act, Schedule I) as of December 13, 2014. It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.
Israel: The NBOMe series of psychoactives became controlled in Israel in May, 2013.
Italy: 25C-NBOMe is a Schedule 1 controlled substance in Italy, meaning it is illegal to possess, distribute, and manufacture.
Japan: 25C-NBOMe is a narcotic drug in Japan effective November 1st, 2015.
Latvia: 25C-NBOMe is a Schedule I controlled substance.
New Zealand: 25C-NBOMe was sold as a designer drug in New Zealand in early 2012, but was withdrawn from sale after a statement by Associate Health Minister Peter Dunne that 25C-NBOMe would be considered to be substantially similar in chemical structure to the illegal hallucinogen DOB, and was therefore a Class C controlled drug analogue.
Russia: Russia became the first country to regulate the NBOME class. The entire NBOMe series of psychoactives became controlled in the Russian Federation starting October, 2011.
Sweden: 25C-NBOMe is classed as Schedule I.
Switzerland: 25C-NBOMe is a controlled substance specifically named under Verzeichnis D.
Turkey:** 25C-NBOMe is a classed as drug and is illegal to possess, produce, supply, or import.
United Kingdom: 25C-NBOMe is a Class A drug in the United Kingdom as a result of the N-benzy

Legal Status

Austria: Since June 26, 2019, 25C-NBOMe is illegal to possess, produce and sell under the SMG. (Suchtmittelgesetz Österreich)
Brazil: Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.
Canada: 25C-NBOMe would be considered Schedule III as it is a derivative of 2,5-dimethoxyphenethylamine.
China: As of October 2015 25C-NBOMe is a controlled substance in China.
Germany: 25C-NBOMe is controlled under Anlage I BtMG (Narcotics Act, Schedule I) as of December 13, 2014. It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.
Israel: The NBOMe series of psychoactives became controlled in Israel in May, 2013.
Italy: 25C-NBOMe is a Schedule 1 controlled substance in Italy, meaning it is illegal to possess, distribute, and manufacture.
Japan: 25C-NBOMe is a narcotic drug in Japan effective November 1st, 2015.
Latvia: 25C-NBOMe is a Schedule I controlled substance.
New Zealand: 25C-NBOMe was sold as a designer drug in New Zealand in early 2012, but was withdrawn from sale after a statement by Associate Health Minister Peter Dunne that 25C-NBOMe would be considered to be substantially similar in chemical structure to the illegal hallucinogen DOB, and was therefore a Class C controlled drug analogue.
Russia: Russia became the first country to regulate the NBOME class. The entire NBOMe series of psychoactives became controlled in the Russian Federation starting October, 2011.
Sweden: 25C-NBOMe is classed as Schedule I.
Switzerland: 25C-NBOMe is a controlled substance specifically named under Verzeichnis D.
Turkey:** 25C-NBOMe is a classed as drug and is illegal to possess, produce, supply, or import.
United Kingdom: 25C-NBOMe is a Class A drug in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause.
United States: Several NBOMe series compounds will be temporarily scheduled in the United States for 2 years with the possibility of an additional year. The temporary scheduling applies to 25C-NBOMe, 25B-NBOMe, and 25I-NBOMe.
Responsible use
Psychedelics
Phenethylamines
25x-NBOMe
25I-NBOMe
25B-NBOMe
25C-NBOMe (Wikipedia)
25C-NBOMe (Erowid Vault)
25C-NBOMe (Isomer Design)
25C-NBOMe (Drugs-Forum)
Discussion
25C-NBOMe, broken down and described (Disregard Everything I Say)

Full	almost immediately after ingestion
Half	7 days
Zero	14 days

25C-NBOMe

Quick Dosage

Dosage

sublingual

Duration

sublingual

How It Feels

Subjective Effects

Physical Effects

Physical(19)

Cognitive & Perceptual Effects

Visual(16)

Pharmacology

Mechanism of Action

Comparative Pharmacology within NBOMe Series

Additional Receptor Activity

Pharmacokinetics

Tolerance

Detection Methods

Urine Detection

Blood and Serum Detection

Standard Drug Panel Inclusion

Confirmatory Methods

Reagent Testing (Harm Reduction)

Interactions

History

Discovery and Research Origins

Emergence in Drug Markets and Fatalities

Scheduling

Current Context

Harm Reduction

Ehrlich Reagent Test — Critical

Sublingual Administration Only

Dose Strictly

Never Redose

Monitor Physiological Warning Signs

Emergency Response

Toxicity & Safety

Confirmed Fatalities

Mechanism of Severe Toxicity

Narrow Therapeutic Window

Cardiovascular Effects

Drug Interactions

Contraindications

Addiction Potential

Overdose Information

Dangerous Interactions

Tolerance

Cross-tolerances

Legal Status

Experience Reports (2)

Tips (5)

See Also

Similar by Effects

Same Class

References (4)

Frequently Asked Questions

Cognitive(15)

Multi-sensory(1)

Transpersonal(3)